PT2698375T - Moduladores de tgr5 e método de utilização dos mesmos - Google Patents

Moduladores de tgr5 e método de utilização dos mesmos

Info

Publication number: PT2698375T
Authority: PT; Portugal
Prior art keywords: tgr5 modulators; tgr5; modulators
Prior art date: 2008-11-19

Application number

PT131923948T

Other languages

English (en)

Inventor

Pellicciari Roberto

Original Assignee

Intercept Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-19

Filing date

2009-11-19

Publication date

2018-05-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41668454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2698375(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-11-19 Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc

2018-05-25 Publication of PT2698375T publication Critical patent/PT2698375T/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Immunology (AREA)
Cardiology (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Child & Adolescent Psychology (AREA)
Gastroenterology & Hepatology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PT131923948T 2008-11-19 2009-11-19 Moduladores de tgr5 e método de utilização dos mesmos PT2698375T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP08169462		2008-11-19

Publications (1)

Publication Number	Publication Date
PT2698375T true PT2698375T (pt)	2018-05-25

Family

ID=41668454

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT131923948T PT2698375T (pt)	2008-11-19	2009-11-19	Moduladores de tgr5 e método de utilização dos mesmos
PT97600571T PT2376519E (pt)	2008-11-19	2009-11-19	Moduladores de tgr5 e métodos da sua utilização

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT97600571T PT2376519E (pt)	2008-11-19	2009-11-19	Moduladores de tgr5 e métodos da sua utilização

Country Status (23)

Country	Link
US (5)	US8114862B2 (pt)
EP (2)	EP2376519B1 (pt)
JP (5)	JP5535233B2 (pt)
KR (2)	KR101789960B1 (pt)
CN (2)	CN102325784B (pt)
AU (1)	AU2009316566B9 (pt)
BR (1)	BRPI0921983B8 (pt)
CA (1)	CA2744189C (pt)
DK (2)	DK2376519T3 (pt)
EA (2)	EA030681B1 (pt)
ES (2)	ES2663948T3 (pt)
HK (1)	HK1205132A1 (pt)
HU (1)	HUE039171T2 (pt)
IL (3)	IL212969A (pt)
LT (1)	LT2698375T (pt)
MX (1)	MX2011005295A (pt)
NO (1)	NO2698375T3 (pt)
PL (2)	PL2376519T3 (pt)
PT (2)	PT2698375T (pt)
SG (1)	SG10201400162QA (pt)
SI (1)	SI2698375T1 (pt)
WO (1)	WO2010059853A1 (pt)
ZA (1)	ZA201104077B (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2002308295B2 (en)	2001-03-12	2007-08-23	Intercept Pharmaceuticals, Inc.	Steroids as agonists for FXR
US10987362B2 (en)	2004-03-12	2021-04-27	Intercept Pharmaceuticals, Inc.	Treatment of fibrosis using FXR ligands
SI2712617T1 (sl)	2004-03-12	2017-01-31	Intercept Pharmaceuticals, Inc.	Zdravljenje fibroze z uporabo Fxr ligandov
ITMI20050912A1 (it)	2005-05-19	2006-11-20	Erregierre Spa	Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
CA2928178C (en)	2007-01-19	2019-09-10	Intercept Pharmaceuticals, Inc.	Tgr5 modulators and methods of use thereof
EP2324046B1 (en)	2008-07-30	2014-09-03	Intercept Pharmaceuticals, Inc.	Tgr5 modulators and methods of use thereof
NO2698375T3 (pt) *	2008-11-19	2018-07-21
JP2012509892A (ja)	2008-11-26	2012-04-26	サティオゲンファーマシューティカルズ，インク．	サティオゲン類を含有する組成物及び使用の方法
WO2010062861A2 (en)	2008-11-26	2010-06-03	Satiogen Pharmaceuticals, Inc.	Bile acid recycling inhibitors for treatment of obesity and diabetes
ES2552657T3 (es)	2010-05-26	2015-12-01	Satiogen Pharmaceuticals, Inc.	Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
SG11201401849QA (en)	2011-10-28	2014-05-29	Lumena Pharmaceuticals Inc	Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
SG10201406155QA (en)	2011-10-28	2014-11-27	Lumena Pharmaceuticals Inc	Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
CA2877122C (en)	2012-06-19	2020-04-28	Intercept Pharmaceuticals, Inc.	Preparation, uses and solid forms of obeticholic acid
US9982008B2 (en)	2012-06-19	2018-05-29	Intercept Pharmaceuticals, Inc.	Preparation and uses of obeticholic acid
EP2906946A1 (en)	2012-10-09	2015-08-19	The Procter & Gamble Company	Method of identifying or evaluating beneficial actives and compositions containing the same
CN110151591A (zh)	2012-10-09	2019-08-23	宝洁公司	鉴定协同化妆品组合的方法
US9884066B2 (en)	2013-06-06	2018-02-06	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Bile acid-basic amino acid conjugates and uses thereof
CN105636984A (zh) *	2013-06-13	2016-06-01	法斯特弗沃德制药有限公司	用于治疗慢性炎症和预防胃肠道癌或纤维化的cd40信号转导抑制剂和其他化合物，该其他化合物是胆汁酸、胆汁酸衍生物、tgr5受体激动剂、fxr激动剂或其组合
US10202601B2 (en)	2013-11-22	2019-02-12	Mina Therapeutics Limited	C/EBPα short activating RNA compositions and methods of use
EP3149019B1 (en)	2014-05-29	2019-12-04	Bar Pharmaceuticals S.r.l.	Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases
US20180236064A1 (en) *	2014-10-03	2018-08-23	Mayo Foundation For Medical Education And Research	Targeting tgr5 to treat disease
HK1243930A1 (zh) *	2014-11-06	2018-07-27	英安塔制药有限公司	作爲fxr/tgr5激动剂的胆汁酸类似物和其使用方法
TWI688571B (zh)	2014-11-19	2020-03-21	英商Ｎｚｐ英國有限公司	化合物（四）
PL3221331T3 (pl)	2014-11-19	2020-03-31	NZP UK Limited	Steroidy, 6-alkilo-7-hydroksy-4-en-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
WO2016079518A1 (en)	2014-11-19	2016-05-26	Dextra Laboratories Limited	5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
CN107108688B (zh)	2014-11-19	2019-10-29	Nzp英国有限公司	作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇
CN105985396A (zh) *	2015-02-16	2016-10-05	苏州泽璟生物制药有限公司	氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
CN111116699B (zh) *	2015-04-28	2023-02-28	江苏豪森药业集团有限公司	胆酸衍生物及其制备方法和医药用途
TW201700447A (zh) *	2015-06-19	2017-01-01	英特賽普醫藥品公司	Tgr5調控劑及其用法
US10800807B2 (en) *	2015-06-19	2020-10-13	Intercept Pharmaceuticals, Inc.	TGR5 modulators and methods of use thereof
US11072631B2 (en) *	2015-09-24	2021-07-27	Intercept Pharmaceuticals, Inc.	Methods and intermediates for the preparation bile acid derivatives
UA123948C2 (uk) *	2015-10-07	2021-06-30	Інтерсепт Фармасьютікалз, Інк.	Модулятори фарнезоїдного х-рецептора
CN109467585A (zh) *	2016-03-11	2019-03-15	深圳市塔吉瑞生物医药有限公司	用于预防或治疗fxr-介导疾病的胆烷酸化合物
IL262342B (en)	2016-04-13	2022-08-01	Intercept Pharmaceuticals Inc	An fxr agonist for use as a medicament for the treatment or prevention of hepatocellular carcinoma
GB201608777D0 (en)	2016-05-18	2016-06-29	Dextra Lab Ltd	Compounds
JP7036805B2 (ja)	2016-05-29	2022-03-15	深▲じぇん▼市▲絵▼云生物科技有限公司	肝疾患関連バイオマーカーおよびその使用方法
WO2018005794A2 (en) *	2016-07-01	2018-01-04	Venenum Biodesign Llc	Novel non-systemic tgr5 agonists
WO2018222701A1 (en) *	2017-05-30	2018-12-06	Intercept Pharmaceuticals, Inc.	Treatment of renal diseases with a bile acid derivative
CN109021056B (zh) *	2017-06-09	2021-03-09	博瑞生物医药（苏州）股份有限公司	法尼酯x受体激动剂
CA3070837A1 (en)	2017-07-24	2019-01-31	Intercept Pharmaceuticals, Inc.	Isotopically labeled bile acid derivatives
WO2019048631A1 (en)	2017-09-08	2019-03-14	Mina Therapeutics Limited	SMALL HNF4A ACTIVATOR RNA COMPOSITIONS AND METHODS OF USE
GB201812382D0 (en)	2018-07-30	2018-09-12	Nzp Uk Ltd	Compounds
US20220096495A1 (en) *	2019-02-04	2022-03-31	Intercept Pharmaceuticals, Inc.	Treatment and prevention of intestinal inflammatory diseases with a bile acid derivative
CN116925168A (zh)	2019-08-23	2023-10-24	深圳云合医药科技合伙企业(有限合伙)	胆汁酸衍生物及其组合物和应用
WO2021071837A1 (en)	2019-10-07	2021-04-15	Kallyope, Inc.	Gpr119 agonists
BR112022017039A2 (pt)	2020-02-28	2022-11-16	Kallyope Inc	Agonistas de gpr40
JP2023526625A (ja)	2020-05-19	2023-06-22	キャリーオペ，インク．	Ａｍｐｋアクチベーター
CN116390925A (zh)	2020-06-26	2023-07-04	卡尔优普公司	Ampk活化剂
KR102693566B1 (ko) *	2020-07-03	2024-08-08	주식회사 큐라클	지방간 질환의 예방 또는 치료를 위한 약학적 조성물
CN113774142A (zh) *	2021-10-11	2021-12-10	北京化工大学	Tgr5在制备治疗肠癌药物及诊断性试剂盒中的应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0101554B1 (en)	1982-07-29	1986-10-15	Lehner A.G.	New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same
IT1206112B (it)	1983-04-29	1989-04-14	Lehner Ag	Nuovi derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
IT1212835B (it)	1983-08-18	1989-11-30	Lehner Ag	Derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
US4892868A (en) *	1984-08-17	1990-01-09	Gipharmex, S.P.A.	Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions
IT1196377B (it) *	1984-12-21	1988-11-16	Lehner Ag	Derivati di acidi biliari,procedimento per la loro preparazione e relative composizioni farmaceutiche
IT1223313B (it) *	1987-10-20	1990-09-19	Gipharmex Spa	Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono
US5175320A (en) *	1989-04-17	1992-12-29	Giuliani S.P.A.	Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
IT1229570B (it) *	1989-04-17	1991-09-04	Giuliani Spa	Derivati fluorurati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono.
US5055477A (en) *	1989-12-13	1991-10-08	Mitsubishi Kasei Corporation	Pyrazolyl acrylic acid derivatives, useful as systemic fungicides for plant and material protection
WO1997028149A1 (en)	1996-02-02	1997-08-07	Merck & Co., Inc.	Method for raising hdl cholesterol levels
GB9604242D0 (en)	1996-02-28	1996-05-01	Glaxo Wellcome Inc	Chemical compounds
GB9606805D0 (en)	1996-03-30	1996-06-05	Glaxo Wellcome Inc	Medicaments
US5689791A (en)	1996-07-01	1997-11-18	Xerox Corporation	Electrically conductive fibers
JP2000514807A (ja)	1996-07-12	2000-11-07	スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー	レプチン耐性の新規な治療
US6008237A (en) *	1997-12-19	1999-12-28	Merck & Co., Inc.	Arylthiazolidinedione derivatives
ES2317688T3 (es)	1998-01-29	2009-04-16	Amgen Inc.	Moduladores ppar-gamma.
WO2000025134A1 (en)	1998-10-23	2000-05-04	Glaxo Group Limited	Assays for ligands for nuclear receptors
ES2326850T3 (es)	1998-12-23	2009-10-20	Glaxo Group Limited	Ensayos para ligandos de receptores nucleares.
WO2000040965A1 (en)	1999-01-07	2000-07-13	Tularik, Inc.	Fxr receptor-mediated modulation of cholesterol metabolism
US20020132223A1 (en)	1999-03-26	2002-09-19	City Of Hope	Methods for modulating activity of the FXR nuclear receptor
EP1473042B1 (en)	1999-03-26	2006-06-21	City of Hope	Screening for FXR receptor modulators
DE60013417T2 (de)	1999-03-26	2005-09-15	City Of Hope, Duarte	Verfahren zum screenen von fxr-rezeptormodulatoren
US6906057B1 (en) *	1999-06-11	2005-06-14	Allergan, Inc.	Methods for modulating FXR receptor activity
BR0011743A (pt)	1999-06-11	2002-03-05	Allergan Sales Inc	Método para modular a atividade de receptor de fxr
US6559188B1 (en) *	1999-09-17	2003-05-06	Novartis Ag	Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
EP1284728A4 (en)	1999-10-22	2004-05-19	Merck & Co Inc	MEDICINES FOR TREATING ADDICTIC ADDICTION
EP1273659A4 (en)	2000-04-12	2004-04-21	Takeda Chemical Industries Ltd	G-PROTEIN COUPLED RECEPTOR PROTEIN AND ITS DNA
US6627636B2 (en) *	2000-06-15	2003-09-30	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
WO2002020463A2 (en)	2000-09-05	2002-03-14	Tularik Inc.	Fxr modulators
US20020119958A1 (en)	2001-02-13	2002-08-29	Shinichiro Tojo	Therapeutic agent for hyperlipidemia
AU2002308295B2 (en) *	2001-03-12	2007-08-23	Intercept Pharmaceuticals, Inc.	Steroids as agonists for FXR
US7354726B2 (en)	2001-04-12	2008-04-08	Takeda Pharmaceutical Company Limited	Screening method
EP1285914B1 (en) *	2001-08-13	2007-12-19	PheneX Pharmaceuticals AG	Nr1h4 nuclear receptor binding compounds
EP1423113A4 (en)	2001-08-13	2007-04-18	Phenex Pharmaceuticals Ag	NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS
WO2003016280A1 (en)	2001-08-13	2003-02-27	Lion Bioscience Ag	Nr1h4 nuclear receptor binding compounds
US20030144360A1 (en)	2001-11-19	2003-07-31	Allergan Sales, Inc.	Composition and method for modulating BAR/FXR receptor activity
WO2003080803A2 (en)	2002-03-21	2003-10-02	Smithkline Beecham Corporation	Methods of using farnesoid x receptor (fxr) agonists
WO2003086303A2 (en)	2002-04-12	2003-10-23	The University Of Chicago	Farnesoid x-activated receptor agonists
US6987121B2 (en)	2002-04-25	2006-01-17	Smithkline Beecham Corporation	Compositions and methods for hepatoprotection and treatment of cholestasis
RU2310620C2 (ru)	2002-06-19	2007-11-20	Аваилвс Корпорейшн	Стеновой материал из искусственного камня
ITMI20021532A1 (it)	2002-07-12	2004-01-12	Roberto Pellicciari	Composti chimici
US7319109B2 (en)	2002-11-22	2008-01-15	Smith Kline Beecham Corporation	Farnesoid X receptor agonists
EP1591120A4 (en)	2003-01-28	2009-06-10	Takeda Chemical Industries Ltd	RECEPTOR AGONISTS
US20070015796A1 (en)	2003-09-26	2007-01-18	Smithkline Beecham Corporation	Compositions and methods for treatment of fibrosis
EP1568706A1 (en)	2004-02-26	2005-08-31	Intercept Pharmaceuticals, Inc.	Novel steroid agonist for FXR
SI2712617T1 (sl)	2004-03-12	2017-01-31	Intercept Pharmaceuticals, Inc.	Zdravljenje fibroze z uporabo Fxr ligandov
ITMI20050912A1 (it)	2005-05-19	2006-11-20	Erregierre Spa	Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
EP2040713B1 (en)	2006-06-27	2014-06-18	Intercept Pharmaceuticals Inc.	Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
EP1947108A1 (en)	2007-01-19	2008-07-23	Intercept Pharmaceuticals, Inc.	TGR5 modulators and methods of use thereof
CA2928178C (en)	2007-01-19	2019-09-10	Intercept Pharmaceuticals, Inc.	Tgr5 modulators and methods of use thereof
NO2698375T3 (pt) *	2008-11-19	2018-07-21

2009
- 2009-11-19 NO NO13192394A patent/NO2698375T3/no unknown
- 2009-11-19 EA EA201400258A patent/EA030681B1/ru not_active IP Right Cessation
- 2009-11-19 MX MX2011005295A patent/MX2011005295A/es active IP Right Grant
- 2009-11-19 KR KR1020167028159A patent/KR101789960B1/ko not_active Expired - Fee Related
- 2009-11-19 EP EP09760057.1A patent/EP2376519B1/en active Active
- 2009-11-19 LT LTEP13192394.8T patent/LT2698375T/lt unknown
- 2009-11-19 EP EP13192394.8A patent/EP2698375B1/en active Active
- 2009-11-19 BR BRPI0921983A patent/BRPI0921983B8/pt not_active IP Right Cessation
- 2009-11-19 CN CN200980154713.0A patent/CN102325784B/zh active Active
- 2009-11-19 DK DK09760057.1T patent/DK2376519T3/da active
- 2009-11-19 SI SI200931820T patent/SI2698375T1/sl unknown
- 2009-11-19 ES ES13192394T patent/ES2663948T3/es active Active
- 2009-11-19 KR KR1020117014037A patent/KR101667436B1/ko not_active Expired - Fee Related
- 2009-11-19 US US12/622,123 patent/US8114862B2/en active Active
- 2009-11-19 SG SG10201400162QA patent/SG10201400162QA/en unknown
- 2009-11-19 EA EA201170714A patent/EA020140B1/ru unknown
- 2009-11-19 DK DK13192394.8T patent/DK2698375T3/en active
- 2009-11-19 PL PL09760057T patent/PL2376519T3/pl unknown
- 2009-11-19 PT PT131923948T patent/PT2698375T/pt unknown
- 2009-11-19 WO PCT/US2009/065188 patent/WO2010059853A1/en not_active Ceased
- 2009-11-19 HU HUE13192394A patent/HUE039171T2/hu unknown
- 2009-11-19 ES ES09760057.1T patent/ES2458168T3/es active Active
- 2009-11-19 JP JP2011537624A patent/JP5535233B2/ja not_active Expired - Fee Related
- 2009-11-19 CA CA2744189A patent/CA2744189C/en active Active
- 2009-11-19 AU AU2009316566A patent/AU2009316566B9/en active Active
- 2009-11-19 PT PT97600571T patent/PT2376519E/pt unknown
- 2009-11-19 CN CN201410532890.0A patent/CN104370990A/zh active Pending
- 2009-11-19 PL PL13192394T patent/PL2698375T3/pl unknown
2011
- 2011-05-18 IL IL212969A patent/IL212969A/en active IP Right Grant
- 2011-06-01 ZA ZA2011/04077A patent/ZA201104077B/en unknown
- 2011-12-07 US US13/313,689 patent/US8445472B2/en not_active Expired - Fee Related
2013
- 2013-04-26 US US13/871,492 patent/US9650409B2/en not_active Expired - Fee Related
2014
- 2014-04-22 JP JP2014088019A patent/JP2014159456A/ja not_active Withdrawn
2015
- 2015-06-10 HK HK15105499.8A patent/HK1205132A1/xx unknown
- 2015-08-14 JP JP2015160141A patent/JP2015232020A/ja active Pending
2016
- 2016-03-29 IL IL244812A patent/IL244812B/en active IP Right Grant
2017
- 2017-04-07 US US15/482,107 patent/US20180016295A1/en not_active Abandoned
- 2017-04-19 JP JP2017083045A patent/JP2017132803A/ja not_active Withdrawn
2018
- 2018-03-27 JP JP2018059922A patent/JP2018100304A/ja not_active Withdrawn
2019
- 2019-02-12 IL IL264796A patent/IL264796B/en active IP Right Grant
2020
- 2020-11-09 US US17/092,612 patent/US20210269473A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN104370990A (zh)	2015-02-25
JP2018100304A (ja)	2018-06-28
US8114862B2 (en)	2012-02-14
KR101667436B1 (ko)	2016-10-18
EP2376519B1 (en)	2013-11-13
US9650409B2 (en)	2017-05-16
EA201400258A1 (ru)	2015-02-27
IL244812B (en)	2019-03-31
KR20110086177A (ko)	2011-07-27
PL2376519T3 (pl)	2014-04-30
AU2009316566B9 (en)	2014-05-15
EP2698375A2 (en)	2014-02-19
KR20160122272A (ko)	2016-10-21
PL2698375T3 (pl)	2018-08-31
EA030681B1 (ru)	2018-09-28
BRPI0921983B8 (pt)	2021-05-25
US20140100209A1 (en)	2014-04-10
CN102325784A (zh)	2012-01-18
WO2010059853A1 (en)	2010-05-27
EA020140B1 (ru)	2014-08-29
AU2009316566B2 (en)	2014-04-17
ZA201104077B (en)	2012-02-29
JP5535233B2 (ja)	2014-07-02
SI2698375T1 (sl)	2018-10-30
JP2015232020A (ja)	2015-12-24
AU2009316566A2 (en)	2011-07-14
PT2376519E (pt)	2014-02-20
US20100152151A1 (en)	2010-06-17
US20120115832A1 (en)	2012-05-10
IL264796B (en)	2020-11-30
US8445472B2 (en)	2013-05-21
DK2698375T3 (en)	2018-05-28
CN102325784B (zh)	2014-11-19
CA2744189A1 (en)	2010-05-27
MX2011005295A (es)	2011-06-24
DK2376519T3 (da)	2014-02-03
EP2698375A3 (en)	2014-03-12
EA201170714A1 (ru)	2012-01-30
HUE039171T2 (hu)	2018-12-28
US20180016295A1 (en)	2018-01-18
JP2017132803A (ja)	2017-08-03
HK1166327A1 (en)	2012-10-26
IL244812A0 (en)	2016-05-31
LT2698375T (lt)	2018-07-10
JP2012509348A (ja)	2012-04-19
IL212969A (en)	2016-04-21
JP2014159456A (ja)	2014-09-04
NO2698375T3 (pt)	2018-07-21
IL212969A0 (en)	2011-07-31
ES2458168T3 (es)	2014-04-30
ES2663948T3 (es)	2018-04-17
KR101789960B1 (ko)	2017-10-25
US20210269473A1 (en)	2021-09-02
SG10201400162QA (en)	2014-05-29
AU2009316566A1 (en)	2010-05-27
HK1205132A1 (en)	2015-12-11
EP2376519A1 (en)	2011-10-19
BRPI0921983B1 (pt)	2021-04-20
EP2698375B1 (en)	2018-02-21
CA2744189C (en)	2016-10-11
BRPI0921983A2 (pt)	2018-07-10

Publication	Publication Date	Title
ZA201104077B (en)	2012-02-29	Tgr5 modulators and method of use thereof
EG27167A (en)	2015-08-26	Microemulsifiers and methods of making and using same
EP2299931A4 (en)	2015-07-01	CLOSURE DEVICE AND METHODS OF USE THEREOF
ZA201104463B (en)	2012-09-26	Compounds and methods of use
EP2340244A4 (en)	2012-07-25	COMPOUNDS AND APPLICATION PROCEDURES
ZA201008483B (en)	2012-03-28	Diazacarbazoles and methods of use
IL199945A0 (en)	2010-04-15	23-substituted bile acids as tgr5 modulators and methods of use thereof
EP2262450A4 (en)	2014-04-09	IMPLANTS AND METHODS OF USE
IL205977A0 (en)	2010-11-30	5-anilinoimidazopyridines and methods of use
GB0809278D0 (en)	2008-06-25	Scooter and method of use thereof
ZA201102076B (en)	2014-08-27	Herbicide-resistant ahas-mutants and methods of use
EP2262754A4 (en)	2012-03-14	MINOCYCLINE COMPOUNDS AND METHODS OF USE THEREOF
IL209548A0 (en)	2011-01-31	Diazacarbazoles and methods of use
EP2242854A4 (en)	2012-08-15	COMPOUNDS AND USES THEREOF
IL206125A0 (en)	2010-11-30	Azaindolizines and methods of use
GB0700372D0 (en)	2007-02-14	Device and methods of using device
IL213695A0 (en)	2011-07-31	Adhesive compounds and methods of use thereof
EP2368010A4 (en)	2015-09-09	CONNECTING DEVICE AND METHOD FOR THEIR USE
EP2328441A4 (en)	2013-03-13	CONTAINER AND METHOD FOR ITS USE
GB0900264D0 (en)	2009-02-11	Device and method of making solid beads
ZA201104020B (en)	2014-08-27	Optical device and method of manufacture
TWI370680B (en)	2012-08-11	Camera and method of personality thereof
IL209545A0 (en)	2011-01-31	Substotited pyrroles and methods of use
GB0803070D0 (en)	2008-03-26	Positioning means and method of use thereof
AU2008903571A0 (en)	2008-07-31	Device and method of use